Epizyme submits NDA to US FDA for tazemetostat to treat epithelioid sarcoma

This article was originally published here

Tazemetostat is an oral, first-in-class, EZH2 inhibitor discovered by Epizyme and being developed for a range of cancers and treatment settings. This NDA submission follows a recently conducted

The post Epizyme submits NDA to US FDA for tazemetostat to treat epithelioid sarcoma appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply